Joseph Glorioso III

Joseph Glorioso III, PhD, is the Emeritus Chair of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine, having served as chair for 20 years. He served as the founding editor for Gene Therapy for 20 years. He is a founding member and former president of the American Society of Gene and Cell Therapy and former president of the Dept Chairs of the US Medical School Microbiology and Immunology Departments. He is a fellow of the American Society for Microbiology (ASM) and the American Association for the Advancement of Science (AAAS).

He has had an active NIH supported research program for 40 years and has been active NIH study Section member for several decades. He also Co‑founded and is Chair of the Scientific Advisory Boards of Oncorus, Inc. Cambridge, MA and Coda Biotherapeutics, San Francisco, CA. He is Chair of the Scientific Advisory Council for the Alliance for Cancer Gene Therapy, a non‑profit foundation to support innovative cancer therapies.

Dr. Glorioso’s contributions to science include defining antiviral immune responses to herpes simplex virus (HSV) infection, the genetics of HSV pathogenesis and latency, and mechanisms of HSV infection. He has pioneered the design and application of HSV gene vectors for the treatment of nervous system diseases such as peripheral neuropathies, chronic pain, and brain tumors. He continues to be a worldwide leader in the HSV gene vector field through the creation of innovative gene delivery technologies and the development of manufacturing methods for application of HSV vectors in human clinical trials.